title: The Effect of High Poly Unsaturated Fatty Acid (PUFA) Dietary Supplementation on Inflammatory Status of Patients with Advanced Cervical Cancer on Radiation Treatment.
abstract: OBJECTIVE
  to identify the effect of high-PUFA dietary supplementation on inflammatory status of patients with advanced cervical cancer.
  
  
  METHODS
  a randomized double-blind clinical trial was conducted in patients with advanced cervical cancer who had undergone external radiation therapy at Department of Radiotherapy, Cipto Mangunkusumo Hospital, Jakarta, between April 2013 and April 2014. The inflammatory status was evaluated based on serum prostaglandin E2 (PGE2) levels using ELISA method. The dietary supplementation was isocaloric, isoprotein and contained PUFA with a ratio of -6: -3 fatty acid = 1.27:1 and supplementation without PUFA. Data were analyzed with statistical tests, including Shapiro-Wilk test, independent T-test and Mann-Whitney test.
  
  
  RESULTS
  there was statistically no significant difference on PGE2 level between treatment and control groups (p=0.127). However, there was clinically significant difference, in which the treatment group had reduced PGE2 level by 8.9%; while the control group had increased level by 28.1%.
  
  
  CONCLUSIONS
  dietary supplementation enriched with PUFA can reduce inflammatory status in patients with advanced cervical cancer. Reduced PGE2 level will lower the survival of cancer cells; therefore dietary supplementation enriched with PUFA with a ratio of -6 : -3 fatty acid = 1.27 : 1 along with radiation therapy may improve tumor response to radiation.
authors.affiliation: Faculty of Medicine YARSI University, Jakarta, Indonesia.
authors.forename: Sri
authors.initials: S
authors.lastname: Wuryanti
authors.lastname: Andrijono
authors.lastname: Susworo
authors.forename: Fiastuti
authors.initials: F
authors.lastname: Witjaksono
mesh_terms: D000328:Adult; D019587:Dietary Supplements; D015232:Dinoprostone / Q000097:blood; D004311:Double-Blind Method; D015525:Fatty Acids, Omega-3 / Q000627:therapeutic use*; D043371:Fatty Acids, Omega-6 / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D007249:Inflammation / Q000097:blood*; D008875:Middle Aged; D002583:Uterine Cervical Neoplasms / Q000532:radiotherapy*
chemical_list: D015525:Fatty Acids, Omega-3; D043371:Fatty Acids, Omega-6; D015232:Dinoprostone